Darunavir / ritonavir

Glimepiride

Dosage adjustment may be necessary.

No pharmaceutical opinion available for this interaction.

Mechanism

Darunavir / ritonavir can induce the metabolism (CYP 2C9) and decrease the plasma concentration of Glimepiride.

Darunavir / ritonavir

Pharmacodynamic effects

Recommendations

Alternative solution(s)

Glimepiride

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Monitor for clinical efficacy and adjust the dosage if necessary.

Alternative solution(s)

Metformin, DPP-4 Inhibitors, GLP-1 Agonists

Monitor

Tests

Blood Sugar

Pharmacokinetic parameters

Comment

Ref #3189 : Co-administration of 600 mg rifampicin, a CYP2C9 inducer, and a single dose of glimepiride 1 mg (after 7 days of once daily rifampicin 600 mg) resulted in a 34% in glimepiride AUC. However, no effect on blood glucose was observed in this study.

Comment
Reference
  • 3188
    Glimepiride (Amaryl), Sanofi-Aventis, Québec, Canada, 23 décembre 2016.
  • 3189
    Niemi M, Kivistö KT, Backman JT, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. J Clin Pharmacol 2000; 50: 591-5.